Working through the National Institutes of Health, the White House has licensed research tools and intellectual property for COVID-19 technologies to the UN-backed program Medicines Patent Pool. The technologies will allow manufacturers from low and middle income countries to make COVID-19 vaccines and ramp up testing.
Eleven U.S. technologies including diagnostic tech, research tools and early stage COVID-19 vaccine candidates were included in the list of licensed technologies.
“I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing,” said Tedros Adhanom Ghebreyesus, PhD, director-general of WHO.
